Latest News

Servier and MiNA Therapeutics sign €220m deal

Moa of saRNAs. Small activating RNAs (saRNAs) are double-stranded RNA molecules (dsRNAs) that are precisely matched to gene promoters. The transcription of targeted genes is activated and the proteins that are missing depending on the indication are produced. © MINA Therapeutics


by tg

French Servier SA and the UK’s MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.

Under the agreement, MiNA Therapeutics will use its small activating RNA platform (saRNA) to identify candicate saRNAs that can restore normal cell function in neurological disorders. Servier will be responsible for preclinical and clinical development of lead candidates and will have the rights for the commercialisation of any products resulting from the collaboration. Under the terms of the agreement, MiNA Therapeutics can receive up to €220m including an upfront payment, an exclusivity fee on selected neurological targets and milestone payments as well as royalties.

saRNAs activate gene expression thus unlocking potential for the treatment of neurodegenerative diseases with limited treatment options, particularly in the neurology and immuno-inflammation area. The collaboration is an extension to MiNA Therapeutics’ R&D activities that has been so far focussed on liver cancer.

French biotech investors launch spin-out alliance

Argobio SAS has been kicked off with €50m of committed capital from Kurma Partners, and the state bank Bpifrance. Co-investors include Angelini...

Rentschler Biopharma launches gene therapy subsidiary

Monoclonal antibody specialist Rentschler Biopharma SE is moving forward with the expansion of its geographic footprint and technological porttfolio....

Avantium NV bags money for demo plant

The new grant is part of a €30m financing mix that Avantium and the Groningen consortium announced this January. FDCA is the key building block for...

Servier and MiNA Therapeutics sign €220m deal

Under the agreement, MiNA Therapeutics will use its small activating RNA platform (saRNA) to identify candicate saRNAs that can restore normal cell...

Merry Christmas and a Happy New Year

MaxiVAX and Minaris Regenerative Medicine ink contract

Under the contract, Minaris will be responsible for the GMP manufacturing, freezing and shipping of MVX-ONCO-2, a cell-based immunotherapy for the...

Rentschler Biopharma to produce 100m doses of CureVac vaccine

Rentschler Biopharma SE is preparing large scale cGMP production and formulation of Curevac’s mRNA vaccine CVnCoV. Under a contract, signed in...